Serum and intratumoral levels show conflicting associations with patient outcome (95–97), which may reflect differences in the release of thrombospondin-1 from the tumor microenvironment into the systemic circulation, or its specific localized effects within the tumor environment. The gene discussed is THBS1; the disease is neoplasm.